Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 440

1.

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.

Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44.

PMID:
10325453
2.
3.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT.

Neurology. 1998 Jan;50(1):136-45.

PMID:
9443470
4.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
5.
6.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
7.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group..

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
8.

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

Rogers SL.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. Review.

PMID:
9853200
9.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group..

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
10.

Donepezil for vascular cognitive impairment.

Malouf R, Birks J.

Cochrane Database Syst Rev. 2004;(1):CD004395. Review.

PMID:
14974068
11.

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.

Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03.

PMID:
19176895
13.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group..

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
14.

Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.

Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ.

Dement Geriatr Cogn Disord. 2005;20(6):338-44.

15.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
16.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
17.

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.

Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P.

Int J Geriatr Psychiatry. 2011 May;26(5):536-44. doi: 10.1002/gps.2562.

PMID:
20872778
19.

Goal setting and attainment in Alzheimer's disease patients treated with donepezil.

Rockwood K, Graham JE, Fay S; ACADIE Investigators..

J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):500-7.

20.

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.

Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group..

Neurology. 2004 Aug 24;63(4):651-7.

PMID:
15326237

Supplemental Content

Support Center